Mode
Text Size
Log in / Sign up

Case report and review of TTMV::RARA-positive APL with spinal cord compression in a childDoctors treated a boy with rare leukemia and spinal pressure using special drugs

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider RNA-based fusion testing for suspected APL with atypical presentations and negative conventional testing.

This publication is a case report with a systematic review of published cases, focusing on TTMV::RARA-positive acute promyelocytic leukemia (APL) with spinal cord compression. The scope includes 12 total cases (one index case and 11 published cases from 2020 to 2024). The authors document that extramedullary involvement occurred in 7 of 12 cases. Diagnostic challenges were noted, with conventional FISH or RT-PCR testing negative in 6 of 10 cases. For the index case, a 9-year-old boy, molecular remission was achieved with the addition of venetoclax after an insufficient response to all-trans retinoic acid plus an oral arsenic compound. Spinal cord compression resolution was documented by MRI post-treatment. The authors note that the evidence is limited by a single-case observation and heterogeneous reported data that preclude statistical analysis. They conclude that RNA-based fusion testing may be informative for PML::RARA-negative suspected APL with atypical presentations. Practice relevance is restrained, as optimal diagnostic and therapeutic approaches await validation through collaborative studies.

Doctors treated a nine-year-old boy with a rare form of blood cancer called acute promyelocytic leukemia. His specific type involved a genetic change called TTMV::RARA. He also had severe pressure on his spinal cord that needed urgent care. This situation was very unusual and hard to diagnose with standard tests.

The medical team first tried standard treatments with retinoic acid and an arsenic compound. These medicines did not fully clear the cancer from his body. They then added a third drug called venetoclax to the mix. This change helped his body reach a state where the cancer was no longer detectable in his blood.

Scans showed the pressure on his spine went away after the new treatment plan. Seven out of twelve similar cases seen in recent years had this specific genetic change. Often, standard tests miss this rare type of cancer because they look for different genetic markers. Doctors now suggest using new genetic tests to find these hidden cases earlier.

No major side effects were reported during the ten months of follow-up care. However, experts say more studies are needed to confirm these findings. Working together will help doctors find better ways to treat these rare and difficult cases in the future.

What this means for you:
New genetic tests help find rare leukemia types missed by standard checks.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
This case report describes a 9-year-old boy with TTMV::RARA-positive acute promyelocytic leukemia (APL) presenting with spinal cord compression due to vertebral destruction, a manifestation not previously documented in the literature. Through a systematic review of 11 published cases (2020–2024), we identified both shared and distinctive features of this ultra-rare entity. The patient presented with a 2-year history of progressive hip pain, culminating in neurogenic claudication and urinary retention. Diagnostic evaluation revealed APL-like morphology and immunophenotype (CD33+, MPO+, CD34−, HLA-DR−), negative PML::RARA fluorescence in situ hybridization (FISH), and a high burden of TTMV::RARA fusion detected by RNA sequencing (81,142 copies). Treatment with all-trans retinoic acid (ATRA) plus an oral arsenic compound showed an insufficient response; however, the addition of venetoclax achieved molecular remission, which was maintained through 10 months of follow-up. Magnetic resonance imaging (MRI) documented resolution of spinal compression with fatty marrow replacement post-treatment. The literature review reveals recurring patterns: frequent extramedullary involvement (7/12 cases) and diagnostic challenges with conventional testing (6/10 cases FISH/reverse transcription-polymerase chain reaction (RT-PCR) negative). While limited by a single-case observation and heterogeneous reported data that preclude statistical analysis, this report expands the recognized clinical spectrum of TTMV::RARA APL and documents three previously unreported observations: spinal cord compression as the initial presentation, venetoclax-induced remission, and oral arsenic compound utilization. These findings suggest RNA-based fusion testing may be informative for PML::RARA-negative suspected APL with atypical presentations, although optimal diagnostic and therapeutic approaches await validation through collaborative studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.